Abstract Library

#3677 Myelophthisis as an end-stage outcome of rare metastases in neuroendocrine tumors – A dual case report

Introduction: Intra-abdominal Neuroendocrine Tumors (NETs) usually metastasize to regional lymph nodes, liver, and bone. Myelophthisis (MPT) is the destruction of the medullary microenvironment due to the tumoral invasion of the trabecular space, altering normal hematopoiesis; it’s frequently caused by metastasis of breast, prostate, and lung adenocarcinomas, and neuroblastoma. MPT due to NET is an unrecognized phenomenon with few cases reported, almost exclusively in poorly differentiated NETs.

Conference:

Presenting Author:

Authors: González Devia D, Aldana-Gómez L, Segovia Gómez J, Ortiz-Santacruz C, Mejía-Arango M,

Keywords: Neuroendocrine Tumor, Myelophthisis, Colon tumor, Prostate tumor, End-stage,

#3363 Neuroendocrine prostate cancer: About 4 cases

Introduction: Neuroendocrine tumors of the prostate are rare entities with a very poor prognosis. They can be pure (small or large cell neuroendocrine carcinoma) or mixed. They do not express prostate specific antigen (PSA) or the androgen receptor. Their treatment is based only on chemotherapy based on platinum for the advanced forms.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Kaid M, Benabdellah H,

Keywords: neuroendocrine prostate, poor prognosis,

#1243 Neuroendocrine Carcinomas of the Prostate

Introduction: Since focal neuroendocrine (NE) differentiation in prostate carcinomas represents a frequent phenomenon when NE markers are used for documentation, NE carcinomas are extremely rare form of highly aggressive prostate tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dema A, Taban S, Anderco D, Bardan R, Daminescu L,

Keywords: neuroendocrine, carcinoma, prostate,

#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker

Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Landolfi S

Authors: de Torres I, Castellvi J, Landolfi S, Fernandez S, Alaña L,

Keywords: PTOV-1, chromogranin A, NETs, inmunohistochemistry,

#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model

Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Herbert Schmid

Authors: Schmid H, Chiara L, Nuciforo P,

Keywords: Pasireotide, Everolimus, SOM230, RAD001, somatostatin, prostate, solid tumors,